TTOO.OQ
Latest Trade
1.26USDChange
0.00(0.00%)Volume
244,762Today's Range
-
1.3752 Week Range
-
3.79As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 1.26 |
|---|---|
Open | 1.29 |
Volume | 244,762 |
3M AVG Volume | 168.25 |
Today's High | 1.37 |
Today's Low | 1.25 |
52 Week High | 3.79 |
52 Week Low | 0.48 |
Shares Out (MIL) | 148.49 |
Market Cap (MIL) | 187.10 |
Forward P/E | -4.60 |
Dividend (Yield %) | -- |
T2 Biosystems Reports Q4 Loss Per Share of $0.07
T2 Biosystems Inc Says Entered Into Amendment No.6 To Term Loan Agreement With CRG Servicing Llc On Jan. 25
T2 Biosystems Sees Q4 2020 Revenue $7.8 million
T2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company's T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company's initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The Company offers T2Dx Instrument (T2Dx) and the T2Candida Panel.
Industry
Medical Equipment & Supplies
Contact Info
101 Hartwell Ave
LEXINGTON, MA
02421-3125
United States
+1.781.4571200
http://www.t2biosystems.com/Executive Leadership
John McDonough
Non-Executive Chairman of the Board
John J. Sperzel
President, Chief Executive Officer, Director
John M. Sprague
Chief Financial Officer
Alec Barclay
Chief Operating Officer
Thomas J. Lowery
Chief Scientific Officer
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 10.32 |
Price To Book (MRQ) | 21.38 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 518.39 |
LT Debt To Equity (MRQ) | 518.39 |
Return on Investment (TTM) | -251.66 |
Return on Equity (TTM) | -87.01 |
* T2 BIOSYSTEMS ANNOUNCES PRELIMINARY SECOND QUARTER 2020 FINANCIAL RESULTS
* T2 BIOSYSTEMS ANNOUNCES U.S. LAUNCH OF COVID-19 DIAGNOSTIC TEST Source text for Eikon: Further company coverage:
* T2 BIOSYSTEMS - RECEIVED WRITTEN NOTICE FROM NASDAQ NOTIFYING CO HAD REGAINED COMPLIANCE WITH NASDAQ LISTING RULE Source: (https://bit.ly/2N5fXEf) Further company coverage:
* T2 BIOSYSTEMS REGAINS COMPLIANCE WITH NASDAQ LISTING REQUIREMENTS Source text for Eikon: Further company coverage:
* T2 BIOSYSTEMS ANNOUNCES CHANGES TO BOARD OF DIRECTORS Source text for Eikon: Further company coverage:
* T2 BIOSYSTEMS - ANTICIPATES DEMAND FOR THE T2SARS-COV-2 TEST UPON BEING MADE COMMERCIALLY AVAILABLE FOR CLINICAL USE
* T2 BIOSYSTEMS ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS
* T2 BIOSYSTEMS ANNOUNCES PRELIMINARY FIRST QUARTER 2020 FINANCIAL RESULTS
* T2 BIOSYSTEMS ANNOUNCES WORLDWIDE LICENSING AGREEMENT OF COVID-19, NOVEL CORONAVIRUS ASSAY FROM HACKENSACK MERIDIAN HEALTH’S CENTER FOR DISCOVERY AND INNOVATION
* T2 BIOSYSTEMS RECEIVES MULTIYEAR INNOVATIVE TECHNOLOGY CONTRACT FROM VIZIENT, INC. Source text for Eikon: Further company coverage:
* T2 BIOSYSTEMS INC - ON MAR 9, CO ENTERED INTO AMENDMENT NO. 1 TO EQUITY DISTRIBUTION AGREEMENT WITH CANACCORD GENUITY LLC
* T2 BIOSYSTEMS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS
* T2 BIOSYSTEMS SAYS ON MAY 16, CO & SMC LTD ENTERED INTO A THIRD AMENDMENT AMENDING CERTAIN SUPPLY AGREEMENT DATED AS OF OCT. 10, 2014 - SEC FILING
* T2 BIOSYSTEMS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.